irritable bowel syndrome
Conditions
Interventions
group 1:Health control:rifaximin
group 2:IBS-D without SIBO:rifaximin
group 3:IBS-D with SIBO:rifaximin
group 4:IBS-D :rifaximin
group 5:IBS-D :Pinaverium bromide
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Conform to the Roman III (Rome III) of a patient diagnosed with IBS - D; (2) Aged 18 to 65 years, gender not limited; (3) Be suitable for this drug treatment; (4) Be voluntary to drug treatment, and signed informed consent, the informed consent process in conformity with the relevant provisions of the GCP.
Exclusion criteria
Exclusion criteria: (1) General or special contraindication for the treatment of rifaximin; (2) Combined cardiovascular, cerebrovascular, liver, kidney, hematopoietic system, hyperthyroidism, severe primary diseases such as diabetes, or seriously affect the survival of the disease (such as tumor, etc.) and psychiatric patients; (3) Pregnancy or ready to pregnancy, nursing mothers; (4) Be doubted or have alcohol and drug abuse history; (5) Cannot give adequately informed consent is a cognitive dysfunction; (6) Nearly 2 weeks using the drug in the treatment of IBS, or nearly a month in other clinical trials of patients; (7) Once the researchers think that there is not suitable factor for selected patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| gut flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| IBS-SSS;abdominal symptom score; | — |
Countries
China
Contacts
Public ContactXiaohua Hou
Outcome results
None listed